English (UK)French


Our subsidiary, ACC BioTech, is involved in biotechnology through investments and partnerships with companies such as BrainStorm Cell Therapeutics. This company is at the forefront of the industry in the development of stem cell.

BrainStorm (OTC.BB: BCLI) is an emerging company developing stem cell therapeutic products based on breakthrough technologies. BrainStorm's core technology, NurOwn™, was developed through a collaboration between prominent neurologist, Prof. Eldad Melamed, Head of Neurology of the Rabin Medical Center and member of the Scientific Committee of Michael J. Fox Foundation for Parkinson's Research and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University.

This scientific team is among the first to have successfully demonstrated the physiological release of dopamine from in vitro differentiated bone marrow cells. Moreover, in research conducted by this team, implantation of these cells into the brains of animal models that had been induced to Parkinsonian behavior markedly improved their symptoms. BrainStorm intends to apply the patent-pending technology to the development of innovative autologous cell therapeutic products, NurOwn™, for treatment of neurological diseases.

BrainStorm holds exclusive worldwide rights to commercialize the NurOwn™ technology, through a licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University. The agreement also provides for further research, funded by BrainStorm, to be performed by Prof. Melamed, Dr. Offen and members of their research team at the Felsenstein Medical Research Center. The results of this research are licensed to the Company under the terms of the license agreement. Thus, although a development stage company, BrainStorm has access to the research results of an R&D team comprising 12 experts in the technology, including molecular and cell biologists, pharmacologists and animal model experts.

The Company's efforts are directed at the development of the technology from the lab to the clinic with the main objectives:

  • Developing the cell differentiation process according to FDA guidelines.
  • Demonstrating safety and efficacy first in animals and then in patients.
  • Setting up centralized facilities to provide NurOwn™ therapeutic products and services for transplantation in patients.

The Company intends to enter into strategic partnerships as it progresses towards advanced clinical development and commercialization.